Miconazole nitrate intended for veterinary tablet compression is first micronised because the nitrate salt is practically insoluble in water under Ph. Eur. solubility classification, and dissolution from an unreduced crystal surface is too slow for a meaningful solid oral dosage form. The micronised active has poor flow and may rathole in pharmaceutical hoppers; direct compression is therefore limited to very low drug loads below 10 mg per tablet. For higher strengths, wet granulation with 5% w/w povidone K30 in purified water densifies the active and reduces segregation during transfer. Granulation is carried out in a top-drive high-shear mixer at impeller speed 200–400 rpm and chopper speed 1000–1500 rpm; water addition is controlled by power consumption and stopped before the mass forms large agglomerates that cannot pass a 1.5 mm wet mill screen. Drying in a fluid-bed dryer with inlet air at 50–60 °C continues until loss on drying is below 2.0% w/w by Ph. Eur. 2.2.32; higher residual moisture can promote hydrolysis of the nitrate salt and increase sticking on the tablet press. The dried granulate is milled through a 1.0 mm conical screen at 500 rpm and blended with crospovidone and lactose monohydrate. Fines below 75 µm are controlled by sieving because they migrate during press vibration and cause mass variation outside Ph. Eur. 2.9.40. Lubrication with 0.5% w/w magnesium stearate is kept to 3 minutes at 12 rpm in a bin blender; prolonged lubrication coats the hydrophobic active and retards release. Compression on a rotary press with 10 mm concave tooling at 12–18 kN produces tablet hardness of 80–120 N and friability below 0.8% under Ph. Eur. 2.9.7. Dissolution is tested in 900 mL of 0.1 M hydrochloric acid using Apparatus 2 at 50 rpm per Ph. Eur. 2.9.3; because veterinary-specific dissolution limits are not harmonised, the developer must justify the specification from clinical and stability data.

What limits terminal sterilisation choice for injectable miconazole nitrate suspensions?

The injectable route is constrained by the poor aqueous solubility of miconazole nitrate; a true solution at therapeutic concentration cannot be prepared without a solubiliser, so suspension and cyclodextrin-based solution approaches dominate development. Suspensions are manufactured by high-shear dispersion of micronised active in a vehicle containing 0.1–0.2% w/v polysorbate 80 and 0.5–1.0% w/v sodium carboxymethylcellulose, yielding a viscosity of 20–50 mPa·s at 25 °C measured with a rotational viscometer at 60 rpm. The viscosity range is selected to reduce sedimentation while maintaining syringeability through a 21 G needle. Laser diffraction is used to control particle size to d90 <15 µm; this limit prevents needle occlusion but requires homogenisation under vacuum to avoid air entrapment. Terminal sterilisation at 121 °C for 15 minutes may be considered only after thermal stability studies on the specific suspension confirm no particle growth or excipient degradation; otherwise aseptic filling is required. Sterility is tested by Ph. Eur. 2.6.1, and bacterial endotoxins are controlled by Ph. Eur. 2.6.14 with a limit aligned to the intended species and route; a common parenteral veterinary limit is <2.5 EU/mL. Clear solutions using hydroxypropyl-β-cyclodextrin require a molar ratio of solubiliser to active that must be determined by phase-solubility studies; published data for licensed veterinary miconazole injection is limited, so the ratio cannot be transferred from human formulations. The osmolality of the solution is adjusted with sodium chloride to 280–320 mOsm/kg and checked by Ph. Eur. 2.2.35 to avoid injection-site pain and haemolysis.

Capsule fill weight control and hygroscopicity under tropical distribution conditions

Hard gelatin capsules containing miconazole nitrate are prepared by pre-blending the micronised active with lactose monohydrate in a high-shear mixer for 5 minutes at 300 rpm, followed by geometric dilution with microcrystalline cellulose to improve flow into an auger dosator. Because miconazole nitrate absorbs moisture above 60% RH, the filling suite is maintained below 40% RH and the filled capsules are packaged in aluminium-aluminium blisters. Content uniformity is assessed by Ph. Eur. 2.9.40; for a 10 mg strength capsule, the acceptance value is controlled below 15. In-process mass verification every 30 minutes rejects individual capsules outside ±5% of target fill weight. Dissolution of capsule contents in 900 mL of 0.1 M hydrochloric acid is performed with a sinker under Ph. Eur. 2.9.3. Stress testing under 40 °C/75% RH for 6 months in accordance with ICH Q1A(R2) is used to confirm that the capsule shell and packaged desiccant maintain the active content above 95.0% of label claim.

Miconazole nitrate dusting powders for cutaneous and otic application in small animals are manufactured by low-shear mixing of 2% w/w micronised active with pharmacopoeial-grade talc or maize starch. The carrier is dried before use to below 5% w/w moisture by Ph. Eur. 2.2.32; wet carrier particles form agglomerates that block insufflator nozzles and create uneven dose delivery. The mixture is passed through a 180 µm sieve, and bulk flow is checked by angle of repose below 40° and bulk density between 0.35–0.55 g/mL. Mixing in a V-blender at 20 rpm for 15 minutes is sufficient to achieve blend uniformity with assay values within 90.0–110.0% of label claim by Ph. Eur. 2.2.29; extended mixing causes electrostatic adhesion of the fine active to the stainless steel walls and lowers assay at the discharge port. The powder is packed into HDPE bottles with a desiccant sachet, and the cap is evaluated for child-resistant closure under ISO 8317:2015 where regulatory filing demands it.

When miconazole nitrate is incorporated into feed premixes, does pelleting temperature reduce potency?

Feed premixes are produced by stepwise dilution of miconazole nitrate with lactose, wheat middlings, or calcium carbonate in a ribbon blender to a working concentration of 0.5–2.0% w/w. Homogeneity is verified by withdrawing 10 samples from defined blender locations and analysing them by a validated HPLC method under ICH Q2(R1); the coefficient of variation is maintained below 5%. Carryover into subsequent non-medicated batches is controlled by a cleaning procedure that includes swab sampling and wipe recovery studies; the acceptance limit is derived from the maximum permitted residue in the next feed batch and from the pharmacologically active threshold. When the premix is incorporated at 1–5 kg/tonne into non-food species feed and pelleted, the conditioning temperature is maintained below 70 °C because miconazole nitrate may undergo degradation under high-moisture thermal processing; published data for specific pelleting degradation kinetics in veterinary miconazole feed is limited, so each production line validates potency retention across the die configuration and conditioning time. The final feed is assayed after pelleting and compared with the pre-pelleting level; recovery below 90% triggers reformulation with a heat-protective carrier or pelleting temperature reduction. Production of medicated feed and premixes must comply with EU 2019/6 and local veterinary medicinal product legislation; for food-producing species, maximum residue limits for miconazole are not established in most jurisdictions, so premix use is restricted to non-food species or companion animals under veterinary prescription.

Oral granules require moisture-activated binding that is terminated below the glass transition of povidone

Granules for oral dosing syringes or top dressing on feed are produced by high-shear granulation of the micronised active with lactose monohydrate and pregelatinised starch. The dry blend is loaded into a top-drive high-shear mixer with jacket temperature set to 25 °C; a binder solution of povidone K30 at 5% w/w in purified water is sprayed at 10–20 g/min/kg of dry mass while the impeller runs at 200–400 rpm and the chopper at 1000–1500 rpm. The granulation endpoint is identified by a plateau in impeller power consumption; overwetting produces paste-like agglomerates that cannot pass a 1.5 mm wet mill screen. Drying in a fluid-bed dryer at 45 °C until moisture is 2–3% w/w by Ph. Eur. 2.2.32 keeps the product below the glass transition softening range of povidone and prevents agglomeration during storage. The dried granules are screened to 250–710 µm using Ph. Eur. 2.9.12; fines below 250 µm are recycled at no more than 20% of the batch weight to maintain dissolution consistency. Bulk density is controlled between 0.45–0.60 g/mL to support reproducible filling of oral dosing syringes; a high bulk density causes bridging in the device, while a low density leads to inaccurate volume-based dosing. Final assay is checked by Ph. Eur. 2.2.29, and the granule fraction is packaged in aluminium foil with desiccant to limit moisture uptake.

Solution formulations of miconazole nitrate for otic application require an acidified cosolvent vehicle because the active remains predominantly ionised and soluble at pH below 4. A typical vehicle contains 20–30% w/v propylene glycol, 10–20% w/v ethanol, and a citrate or acetate buffer at pH 3.0–4.0; the exact ratio is determined by shake-flask solubility experiments and HPLC analysis, because published data for the specific veterinary otic miconazole system is limited. The finished solution is protected from light and stored below 25 °C to reduce photodegradation and esterification. Preservative efficacy is verified by Ph. Eur. 5.1.3; a passing result requires at least 3 log reduction of bacterial challenge strains by 14 days and no recovery of fungal challenge after 28 days. Viscosity is maintained below 10 mPa·s at 25 °C to allow dropwise administration without blocking the ear canal. Container-closure compatibility with metering droppers and low-density polyethylene is confirmed by leachables testing under Ph. Eur. 3.1.4 and ICH Q3D where elemental impurities are relevant; the package includes a desiccant because water uptake from the headspace can shift pH above the crystallisation threshold. If a precipitate appears at low storage temperature, the buffer capacity has been exceeded or the cosolvent ratio is too low, and the formulation must be revised with a higher concentration of propylene glycol within the toxicologically acceptable range for the target species.